PROTAC ER Degrader-3
Catalog No. A18519
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
| Catalog Num | A18519 |
|---|---|
| M. Wt | 1220.41 |
| Formula | C71H77N7O12 |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 2158322-29-1 |
| Synonyms | |
| SMILES | OC1=CC=C(/C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[C@@H](C)[C@H](NC([C@H](C)N(C(OC(C)(C)C)=O)C)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)=C(CC)/C8=CC=CC=C8)C=C1 |
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 8.19 mL | 40.97 mL | 81.94 mL |
| 0.5 mM | 1.64 mL | 8.19 mL | 16.39 mL |
| 1 mM | 0.82 mL | 4.1 mL | 8.19 mL |
| 5 mM | 0.16 mL | 0.82 mL | 1.64 mL |
*The above data is based on the productmolecular weight 1220.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
ADOOQ 产品质量保证
We promise all products to perform as described.